NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Advancing MYCO-001 to Bring Safer, More Effective Smoking Cessation Treatment to Market
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance,” covers Mydecine’s partnership with Dr. Matthew Johnson and Johns Hopkins University to advance its lead drug candidate MYCO-001 as a smoking cessation treatment. The company’s phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research with Johns Hopkins. The multi-site NIDA grant-funded trial is the first government-funded study to research psychedelics in more than 50 years. “To date, Mydecine is the only company sponsoring clinical trials utilizing psilocybin to treat nicotine dependence,” the article reads. “With our lead drug candidate MYCO-001 in two clinical trials next year, Mydecine is positioned to bring a safer more effective treatment to market as early as 2024!”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance,” covers Mydecine’s partnership with Dr. Matthew Johnson and Johns Hopkins University to advance its lead drug candidate MYCO-001 as a smoking cessation treatment. The company’s phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research with Johns Hopkins. The multi-site NIDA grant-funded trial is the first government-funded study to research psychedelics in more than 50 years. “To date, Mydecine is the only company sponsoring clinical trials utilizing psilocybin to treat nicotine dependence,” the article reads. “With our lead drug candidate MYCO-001 in two clinical trials next year, Mydecine is positioned to bring a safer more effective treatment to market as early as 2024!”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
